rFIXFc
Phase 3Biologic
rFIXFc is one of 55 biologic programs targeting Hemophilia. It is currently in Phase 3.
2
Indications
5
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
56 competitors in Hemophilia
#DrugCompanyPhaseTrials
1Crixivan
Merck & Co.Approved
Videx
Bristol-Myers SquibbApproved
Hivid
CConrado Roberto Hoffmann Filho
Approved
Zerit
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Cyklokapron
AAmring
Approved
Daklinza
Bristol-Myers SquibbPhase 3
Recombinant Factor VIII
BayerApproved
Antithrombin Concentrate (ATIIIC)
SanofiApproved
Qfitlia
GGenzyme, a Sanofi Company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hemophilia B4 trials
Show 1 more trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rFIXFc. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- BBioverativ Therapeutics Inc.